ProCE Banner Activity

CME

Key Studies in Skin Cancer: Independent Conference Coverage of the 2023 ASCO Annual Meeting

Text Module

Review this text module with accompanying slides to gain expert insight on the most clinically relevant data on melanoma presented at the 2023 ASCO Annual Meeting.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 21, 2023

Expiration: August 20, 2024

No longer available for credit.

Share

Faculty

Jason Luke

Jason Luke, MD, FACP

Associate Director for Clinical Research
Director, Immunotherapy and Drug Development Center
Associate Professor of Medicine
UPMC Hillman Cancer Center 
University of Pittsburgh
Pittsburgh, Pennsylvania

Jeffrey S. Weber

Jeffrey S. Weber, MD, PhD

Professor of Medicine
NYU Grossman School of Medicine
Deputy Director
NYU Langone Health
Laura and Isaac Perlmutter Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Merck Sharp & Dohme Corp. and Regeneron Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc

Target Audience

This program is intended for physicians and other healthcare professionals caring for patients with a skin cancer. 

Program Learning Goal

This activity aims to improve learners’ understanding of how to optimally apply recent practice-changing findings in treating patients with a skin cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify subpopulations of patients with a skin cancer most likely to benefit from a specific treatment plan based on predictive biomarkers

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with a skin cancer

  • Evaluate new data on novel agents and therapeutic approaches for patients with a skin cancer

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Jason Luke, MD, FACP

Associate Director for Clinical Research
Director, Immunotherapy and Drug Development Center
Associate Professor of Medicine
UPMC Hillman Cancer Center 
University of Pittsburgh
Pittsburgh, Pennsylvania

Jason Luke, MD, FACP: consultant/advisor: 7 Hills, AbbVie, Actym, Affivant, Agenus, Alnylam, Alphamab Oncology, Arch Oncology, AstraZeneca, AskGene, Atomwise, Bayer, BioCytics, Bright Peak, Bristol Myers Squibb, Castle, Checkmate, Codiak, Crown, Cugene, Curadev, Day One, Duke Street Bio, Eisai, Elipscience, EMD Serono, Endeavor, Exo, Flame, Fstar, G1 Therapeutics, Genentech, Geneos, Gilead, Glenmark, HotSpot, Ikena, Immatics, Immunocore, Incyte, Instil, IO Biotech, Inzen, Janssen, Kadmon, Kanaph, Ko Bio Labs, Krystal, KSQ, LegoChem, Lyvgen, MacroGenics, Merck, Mersana, Nektar, NeoTX, Novartis, Reflexion, Onc.AI, OncoNano, Partner, Pfizer, PhysIQ, Pioneering Medicines, PsiOxus, Pyxis, Regeneron, Replimmune, Ribon, Riovant, Saros, Servier, STINGthera, STipe, Storm, Sumoitomo, Synlogic, Synthekine, Tempest, Teva, Xilio; researcher (paid to institution): AbbVie, Astellas, AstraZeneca, Bristol Myers Squibb, Corvus, Day One, EMD Serono, Fstar, Genmab, Hot Spot, Ikena, Immatics, Imugene, Incyte, Janux, Kadmon, KAHR, MacroGenics, Merck, Moderna, Nektar, Next Cure, Novartis, Numab, Palleon, Pfizer, Replimmune, Rubius, Scholar Rock, Servier, Synlogic, Takeda, Trishula, Tizona, Tscan, Werewolf, Xencor; data and safety monitoring board: AbbVie, Agenus, Evaxion, Immutep, Shionogi; individual publicly traded stock/stock options: Actym, Alphmab Oncology, Arch Oncology, Duke Street Bio, Elpiscience, Kanaph, NeoTx, ONC.AI, OncoNano, PhysIQ, Pyxis, Saros, STipe, Tempest.

Jeffrey S. Weber, MD, PhD

Professor of Medicine
NYU Grossman School of Medicine
Deputy Director
NYU Langone Health
Laura and Isaac Perlmutter Cancer Center
New York, New York

Jeffrey S. Weber, MD, PhD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Incyte, Merck, Moderna, Pfizer, Regeneron.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from August 21, 2023, through August 20, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.